CD19 and acute lymphoblastic leukemia: Tisagenlecleucel (target antigen CD19) was used for the treatment of B-cell acute lymphoblastic leukemia (ALL) with an overall survival rate of 84%; event-free survival was 69% among children and young adults with relapsed or refractory B-cell ALL [18].